Golden
Envisagenics

Envisagenics

Envisagenics is a biotechnology company founded by Maria Luisa Pineda and Martin Akerman in 2014 and headquartered in New York City, New York using artificial intelligence and RNA sequencing to develop therapeutics to treat genetic diseases.

Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.

Funding

Seed round

On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine. 

Timeline

People

Name
Role
Related Golden topics

Adrian Krainer

Professor & Program Chair



Maria Luisa Pineda

Co-Founder & CEO



Martin Akerman

Co-Founder & CTO



Michael Schatz

Associate Research Professor



Michael Zhang

Professor & Director



Omar Abdel-Wahab

Hematologic Oncologist



Further reading

Title
Author
Link
Type
Date

Microsoft Announces Winners of AI Startup Competition

Meir Orbach

Web



Platform Targeting Genetic Cause of SMA and Like Diseases Supported by $1.5M NIH Grant

Carolina Henriques

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References